english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2023 > Prescrire Drug Awards for 2023
The Prescrire Awards for 2023

The Prescrire Drug Awards for 2023

Le Palmarès des Médicaments This year, none of the drugs we examined represented a major therapeutic advance worthy of a  Pilule d'Or  ("Golden Pill" Award).  Only one drug made the Honours List.
The  Pilule d'Or  ("Golden Pill") is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available. Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.

 

Palme du Médicamenty Blincyto° (blinatumomab) - Amgen
In high-risk first-relapse acute lymphoblastic leukaemia
in children

 

A notable reduction in mortality, demonstrated in two randomised comparative trials in children with high-risk first-relapse ALL, is a clear therapeutic advance that justifies blinatumomab's place on this year's Honours List.


Download the full article:

Télécharger
 FREE  "The Prescrire Awards for 2023" Prescrire Int 2024; 33 (259): 132-134. Free.

 

Back to "The Prescrire Awards for 2023"

©Prescrire April 2024
     

Filet

Enjoy full access to Prescrire International, and support independent information